⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
EMCURE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.5
| Stock Code | EMCURE | Market Cap | 27,899 Cr. | Current Price | 1,472 ₹ | High / Low | 1,586 ₹ |
| Stock P/E | 64.4 | Book Value | 170 ₹ | Dividend Yield | 0.20 % | ROCE | 13.5 % |
| ROE | 11.6 % | Face Value | 10.0 ₹ | DMA 50 | 1,455 ₹ | DMA 200 | 1,369 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.74 % | PAT Qtr | 118 Cr. | PAT Prev Qtr | 125 Cr. |
| RSI | 50.7 | MACD | 9.39 | Volume | 1,06,370 | Avg Vol 1Wk | 1,39,844 |
| Low price | 889 ₹ | High price | 1,586 ₹ | PEG Ratio | -4.76 | Debt to equity | 0.50 |
| 52w Index | 83.6 % | Qtr Profit Var | 35.3 % | EPS | 22.7 ₹ | Industry PE | 29.1 |
📈 Technical Analysis
- Chart Patterns: Stock has rallied from 889 ₹ lows to 1,586 ₹ highs and is consolidating near 1,472 ₹, showing resilience after recent correction.
- Moving Averages: Current price (1,472 ₹) is above 50 DMA (1,455 ₹) and 200 DMA (1,369 ₹), indicating bullish long-term trend with short-term stability.
- RSI: At 50.7, the stock is neutral, suggesting balanced momentum without overbought or oversold signals.
- MACD: Positive (9.39), indicating bullish momentum building.
- Bollinger Bands: Price is near the mid-band, suggesting consolidation with potential breakout.
- Volume Trends: Current volume (1,06,370) is lower than 1-week average (1,39,844), showing reduced participation in recent moves.
📊 Momentum & Signals
- Short-Term Momentum: Neutral to positive, supported by MACD crossover.
- Support Zones: 1,455 ₹ (near-term), 1,369 ₹ (major support at 200 DMA).
- Resistance Zones: 1,500 ₹ (near resistance), 1,586 ₹ (recent high).
- Entry Zone: 1,450–1,470 ₹ if RSI remains stable.
- Exit Zone: 1,500–1,580 ₹ on rebound; strict stop-loss below 1,450 ₹.
- Trend Status: Stock is consolidating with bullish undertones, likely preparing for breakout.
✅ Positive
- Strong fundamentals with ROCE (13.5 %) and ROE (11.6 %) showing profitability.
- EPS at 22.7 ₹ supports earnings strength.
- Dividend yield at 0.20 % provides modest income support.
- Stock trading above both 50 DMA and 200 DMA confirms long-term bullish trend.
⚠️ Limitation
- High P/E (64.4) compared to industry PE (29.1) suggests premium valuation.
- Debt-to-equity ratio at 0.50 is relatively high compared to peers.
- PEG ratio (-4.76) indicates valuation concerns relative to growth.
📉 Company Negative News
- Quarterly PAT declined (118 Cr. vs 125 Cr.), showing earnings pressure.
- High valuation multiples may limit upside in near term.
📈 Company Positive News
- DII holdings increased (+1.74 %), showing strong domestic institutional support.
- Quarterly profit variance (+35.3 %) highlights operational improvement year-on-year.
- FII holdings also increased (+0.30 %), showing foreign investor confidence.
🏭 Industry
- Industry PE at 29.1 is much lower than company PE (64.4), suggesting EMCURE trades at a premium.
- Pharmaceutical sector outlook remains positive with strong demand and growth potential.
🔎 Conclusion
- EMCURE is in a consolidation phase with bullish undertones, supported by positive MACD and neutral RSI.
- Short-term traders may consider entry near 1,450–1,470 ₹ with exit around 1,500–1,580 ₹.
- Long-term investors may hold due to strong fundamentals and sector outlook, but should be cautious of premium valuations and debt levels.